Glossary
:
Legal/Privacy
:
Contact
Product Pipeline :
Hepatitis C
HIV
Hepatitis C
Influenza
Vaccine Market
Hepatitis B
Rotavirus
Mosquito diseases
Breast Cancer
Hepatitis C
PepTcell is applying its breakthrough technology to the development of a new class of T cell therapeutic vaccines that are effective against Hepatitis C. The Hepatitis C virus is comprised of 11
protein
s and there are a number of different strains so one has to discover those
epitope
s that bind, are reactive and are conserved amongst all strains.
Hepatitis C is a major cause of chronic liver disease worldwide and infection may induce progressive liver damage through fibrosis, in 30% of cases this leads to death through liver cancer or liver failure. Current medications are costly and involve a combination of pegylated interferon and Ribavirin however, with early detection and treatment, 50-80% of patients could be stabilised or cured.
It is widely believed that a vaccine for Hepatitis C will be the most or only effective means to stop the spread of this disease. There is currently no commercial vaccine against Hepatitis C.
PepTcell's Hepatitis C vaccine is at the proof of concept stage.